Track Innoviva, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Innoviva, Inc. INVA · Stock Open Innoviva, Inc. in new tab

19.03 USD
P/E
8.12
EPS
2.35
P/B
1.20
ROE
18.02
Beta
0.37
Target Price
34.80 USD
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E8.12
EPS2.35
Book Value15.90
Price to Book1.20
Debt/Equity29.10
% Insiders1.023%
Growth
Revenue Growth-0.02%
Earnings Growth5.90%
Estimates
Forward P/E8.63
Forward EPS2.21
Target Mean Price34.80

DCF valuation

Model fair value for Innoviva, Inc. (INVA)
Result
Sign in to run the valuation for INVA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Buy · mean target 34.80 USD (low 18.00, high 46.00) · as of 11 Nov 2026
Low 18.00
Mean 34.80
High 46.00
Price 19.03
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Innoviva, Inc. Logo Innoviva, Inc. Analysis (INVA)

United States Health Care Official Website Stock

Is Innoviva, Inc. a good investment? Innoviva, Inc. (INVA) is currently trading at 19.03 USD. Market analysts have a consensus price target of 34.80 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 8.12. This relatively low multiple may signal that Innoviva, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Innoviva, Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 2.21.

Investor FAQ

Does Innoviva, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Innoviva, Inc.?

Innoviva, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 2.35.

Company Profile

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Exchange Ticker
NMS (United States) INVA
FRA (Germany) HVE.F
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2015
0.75 USD
Sept. 30, 2015 0.2500
June 30, 2015 0.2500
March 31, 2015 0.2500
▸2014
0.50 USD
Dec. 23, 2014 0.2500
Sept. 18, 2014 0.2500
Stock Splits
Split Date Split Ratio to 1
June 3, 2014 1.241
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion